Cytokine Release Syndrome (CRS) After CAR T Cell or Bispecific T Cell Engager Therapy in Multiple Myeloma

Clinical Scenario

This protocol applies to patients with multiple myeloma who develop cytokine release syndrome (CRS) following treatment with CAR T cell or bispecific T cell engager therapy — a recognised inflammatory complication in this setting.

About This Complication

CRS is a systemic inflammatory response mediated by the activation of T lymphocytes, observed mainly after treatment with BCMA-targeted CAR T cells or bispecific T cell engagers.

Treatment Approach (Partial Overview)

For grade 1 CRS in this setting, initial management centres on supportive care. The complete protocol defines the conditions under which additional interventions are considered — the full structured regimen is available below.

Instant Access to Structured Evidence-Based Regimens

References

CRS is a systemic inflammatory response mediated by the activation of T lymphocytes, observed mainly after treatment with BCMA-targeted CAR T cells or bispecific T cell engagers.
For grade 1 CRS, we recommend supportive care including analgesics and antipyretics. If fever persists (>3 days) and infections are excluded, consider tocilizumab [I, A].

DOI: 10.1038/s41571-025-01041-x

View source ↗